Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A suitably matched unrelated donor is available for the person (either a 9 out of 10 or 10 out of 10 match)
• The treating team is planning to use one of a specific set of reduced-intensity chemotherapy preparation regimens before the transplant (combinations involving fludarabine-melphalan, BEAM or LEAM, fludarabine-busulphan, or fludarabine-treosulfan, at specific doses)
• The transplant is planned to use stem cells collected from the bloodstream (rather than bone marrow)
• The transplant is planned for one of the following blood cancers: AML in remission, ALL in remission, CMML with fewer than 10% blast cells, MDS with fewer than 10% blast cells, NHL, Hodgkin lymphoma, multiple myeloma, CLL, CML in first or second chronic phase, or myelofibrosis
• The person is aged between 16 and 70 years
• People of reproductive potential (those who are not post-menopausal or have not had a surgical procedure to prevent pregnancy) must agree to use highly effective contraception from the start of treatment until 12 months after the transplant

Who may not be able to join:

• The transplant plan involves any technique to alter or manipulate the donated stem cells before transplant (other than storing some cells for possible later use)
• The treatment plan includes alemtuzumab or any other method of removing T cells from the graft, unless it is specifically defined within the trial protocol
• There is a known allergy or sensitivity to any of the study drugs, or a history of allergic reaction to rabbits
• The person is pregnant or breastfeeding
• People of reproductive potential who are not willing to use highly effective contraception during the required period
• Life expectancy is estimated to be less than 8 weeks
• There is an active hepatitis B (HBV) or hepatitis C (HCV) infection
• Certain organ function test results fall outside the required range, specifically: heart pumping function below 45%, kidney filtration rate below a certain level, or elevated liver-related blood test results (confirm specific thresholds with trial site)
• The person is currently enrolled in either the COSI or ALL-RIC clinical trials
• There is a medical reason why the person should not receive any of the specific study drugs used in this trial (thymoglobulin, cyclophosphamide, sirolimus, ciclosporin, and mycophenolate mofetil)
• The person has any other significant health condition affecting organs or body systems that, in the opinion of the treating doctor, would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.